Table 1 Characteristics of patients included in the study (N = 74)
Variable | Value* |
|---|---|
Age (y) | 46.5 ± 19.8 |
Sex, female | 32 (43.2) |
BMI | 25.5 ± 6.1 |
Nasal polyp duration (y) | 8.8 ± 2.0 |
Nasal polyp surgery | |
≥ 1 previous surgery | 61 (82.4) |
≥ 3 previous surgeries | 11 (14.9) |
Time since most recent polyp surgery (y) | 2.5 ± 4.9 |
Bilateral endoscopic NPS | 5.0 ± 2.0 |
SNOT-22 total score | 54.5 ± 28.8 |
Nasal congestion or obstruction score | 3.0 ± 1.0 |
Missing, n (%) | 5 (6.8) |
Loss-of-smell score | 3.0 ± 1.0 |
Missing, n (%) | 5 (6.8) |
Anterior/posterior rhinorrhea score | 2.0 ± 1.0 |
Missing, n (%) | 5 (6.8) |
Patient reported total symptom score | 8.0 ± 2.0 |
Missing, n (%) | 5 (6.8) |
Rhinosinusitis disease severity VAS | 9.0 ± 2.8 |
Missing, n (%) | 16 (21.6) |
Smell VAS | 9.0 ± 2.0 |
Missing, n (%) | 15 (20.3) |
NSAIDs intolerance n (%) | 24 (32.4) |
Positive skin prick test results | 50 (67.6) |
Allergic rhinitis | 46 (62.2) |
RCSS score | 24.0 ± 12.5 |
Missing, n (%) | 3 (6.5) |
RQLQ score | 3.7 ± 1.1 |
Missing, n (%) | 3 (6.5) |
Allergic conjunctivitis | 24 (32.4) |
Atopic keratoconjunctivitis | 3 (4.0) |
Asthma | 46 (62.2) |
FEV1 (L) | 2.7 ± 0.8 |
Missing, n (%) | 2 (4.3) |
FEV1 (% predicted) | 90.5 ± 15.3 |
Missing, n (%) | 2 (4.3) |
ACT score | 18.0 ± 6.8 |
AQLQ (S) score | 4.3 ± 2.80 |
Atopic dermatitis | 10 (13.5) |
EASI score | 34.2 ± 20.0 |
Peak score on NRS for pruritus | 8.5 ± 1.0 |
Peak score on NRS for sleep | 8.0 ± 0.8 |
DLQI score | 24.0 ± 12.5 |
Food allergy | 6 (8.1) |
Oral allergy syndrome | 1 (1.4) |
Urticaria | 4 (5.4) |
Anaphylactic shock | 1 (1.4) |
Eosinophilic esophagitis | 0 (0) |
Chronic spontaneous urticaria | 3 (4.1) |
UAS7 | 12.0 ± 4.0 |
Use of systemic corticosteroids in the preceding 16 weeks | |
Maintenance use | 50 (67.6) |
Median daily dose mg | 6.9 ± 9.3 |
IgE (KUA/L) | 451.5 ± 286.8 |
Missing, n (%) | 17 (23) |
Eosinophils (cells/mm3) | 550.0 ± 500.0 |
Missing, n (%) | 13 (17.6) |